EuroBiotech—More articles of note

Newspapers

> The team tasked with clearing Redx’s debt disclosed how it came to offload a BTK inhibitor to Loxo Oncology for $40 million. Loxo was up against a clutch of other companies in the scrap to buy the drug. But Loxo  was able to beat the competition, having previously held preliminary discussions about the asset, beating the lowball bids of rivals who hadn’t and moving faster than the one other company that had. Filing

> Lundbeck penciled in a fall 2017 completion date for a phase 1 trial of its Alzheimer’s vaccine. The Danish drugmaker wrapped up enrollment in the trial of the vaccine recently, teeing it up to start learning about the clinical safety of a vaccine designed to induce beta-amyloid-targeting antibodies. Report (PDF)

> Zealand Pharma priced its IPO. The Danish biotech offloaded more than 4 million shares at close to $18 a piece, resulting in it grossing $78 million, more than it initially targeted. Zealand will use most of the money to fund clinical development of glepaglutide for the treatment of short bowel syndrome. Release  

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Neovacs raised €6 million in a private placement. The French biotech tapped U.S. institutional investors for the cash, which enables it to complete mid-phase trials of IFNalpha Kinoid in lupus and dermatomyositis. Statement

> A second phase 3 trial of Motif Bio’s iclaprim completed its treatment stage. The milestone moves Motif Bio a step closer to gathering the data it hopes will position it to win approval of the antibiotic. Release  

> Faron Pharmaceuticals’ phase 3 acute respiratory distress syndrome trial came through a meeting of the data monitoring committee. Statement 


 

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.